International Panel Released New CAR T-Cell Guidelines
Updated protocols for autoimmune therapy aim to address safety concerns following clinical trial fatalities.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you trust that new medical cell therapies are adequately tested before use in patients?
An international panel of medical societies has issued updated guidelines for the use of CAR T-cell therapy in patients with autoimmune diseases. The recommendations, published October 5, seek to standardize clinical practice and manage new toxicities observed when oncologic cell therapies are applied to autoimmune conditions.
Why it matters
The guidelines were released to improve patient safety and clinical consistency after three patient fatalities forced companies like Novartis and Bristol Myers Squibb to pause autoimmune-focused CAR T-cell trials in August. Standardizing the approach is essential as the therapy expands from cancer treatment to autoimmune indications.
The guidelines draw on 10 years of experience with oncologic CAR T-cell therapy, specifically addressing the 3 patient fatalities recorded in trials paused in August. The framework mandates that these treatments occur within clinical trials or via multidisciplinary teams at specialized centers.
The players
European Society for Blood and Marrow Transplantation
An international scientific organization that coordinates research and standards for blood and marrow transplantation.
International Society for Cell and Gene Therapy
A global professional society focused on the clinical translation of cell and gene therapies.
Novartis
A multinational pharmaceutical company with a significant footprint in the development of CAR T-cell technologies.
Bristol Myers Squibb
A biopharmaceutical company active in immuno-oncology and the development of cellular therapies.
The details
CAR T-cell therapy involves genetically modifying a patient's T-cells—a type of white blood cell critical to the immune system—to target specific markers. When adapted for autoimmune diseases, these modified cells can trigger unexpected toxicities not typically seen in cancer treatment. The new guidance mandates collaborative management between cell therapists and specialists such as rheumatologists or neurologists to mitigate these risks.
Timeline
2024: Original release of recommendations.
August 2026: Novartis and Bristol Myers Squibb paused trials.
October 5, 2026: Updated guidelines published in The Lancet Rheumatology.
The Tech Race
The field is transitioning from proven oncologic applications to more complex autoimmune indications, a shift marked by the 2026 suspension of Novartis and Bristol Myers Squibb CAR T-cell trials. These new guidelines mark a necessary step in aligning clinical standards with the higher safety risks inherent in these new patient populations.
Patients currently seeking CAR T-cell therapy for autoimmune conditions will see increased oversight, as providers are now urged to report all treated cases to centralized registries like the EBMT Registry. Clinical access will be prioritized for those within controlled trials or at centers with dual expertise in hematology and autoimmunity.
The takeaway
The move to adapt CAR T-cell therapy for autoimmune disorders is entering a period of increased regulatory scrutiny to address unforeseen toxicities. Researchers and clinicians should track the EBMT Registry reports to see if new safety protocols effectively reduce the mortality rates observed in 2026.
Further reading
For broader context on current developments, visit the Biotech section.
Live Poll
Do you trust that new medical cell therapies are adequately tested before use in patients?
